◆英語タイトル:Renova Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11287
◆発行会社(調査会社):
GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Renova Therapeutics Inc (Renova) is a drug development company that focuses on the development of peptide infusion therapies and gene therapy treatments for cardiovascular and metabolic diseases. The company’s pipeline products include RT-100, RT-200, RT-110, RT-400, RT-210 and RT-300. Its RT-100 is a single-dose treatment designed for congestive heart failure. Renova’s RT-200 is a gene therapy in preclinical stage for the patients with type 2 diabetes. The company’s RT-400 is a peptide infusion therapy for the treatment of acute decompensated heart failure; and RT-300 for the treatment of pulmonary hypertension. Its proprietary paracrine gene therapy treatments also unlock the potential for the treatment of other chronic diseases such as non-alcoholic fatty liver disease, obesity, metabolic syndrome, and others. Renova is headquartered in San Diego, California, the US.
Renova Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Renova Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Renova Therapeutics Raises USD7.52 Million in Series C Financing 10
Partnerships 11
Renova Therapeutics Enters into Agreement with Janssen Pharma 11
Licensing Agreements 12
Renova Therapeutics Enters into Licensing Agreement with Research Development Foundation 12
Renova Therapeutics Enters into Licensing Agreement with Stanford University 13
Renova Therapeutics Enters into Licensing Agreement with Research Development Foundation 14
Renova Therapeutics Inc – Key Competitors 15
Renova Therapeutics Inc – Key Employees 16
Renova Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Product News 18
08/02/2017: PLOS ONE publishes results of cardiac-directed catalytically inactive AC6 in mice after sustained ß-adrenergic stimulation 18
May 02, 2017: Industry leaders join Renova Therapeutics to lead preclinical programs into clinical development 19
02/27/2017: CEO and Co-founder of Renova Therapeutics to present at Novel Cardiovascular Therapeutics Summit 20
Clinical Trials 21
Jan 11, 2018: Renova Therapeutics to present key components of FLOURISH gene therapy trial for the treatment of heart failure at Keystone Symposium 21
Dec 14, 2017: FDA Grants Fast Track Designation to Renova Therapeutics RT-100 AC6 Gene Transfer for the Treatment of Heart Failure 22
Jul 17, 2017: Urocortin 2 gene transfer increases glucose disposal and insulin sensitivity in type 2 diabetes 23
Apr 11, 2017: ‘Human Gene Therapy’ publishes review of randomized clinical trials of gene transfer for heart failure with reduced ejection fraction 24
Jan 05, 2017: Renova Therapeutics selects Worldwide Clinical Trials as its Clinical Research Organization for Phase 3 trial of RT-100 AC6 gene transfer 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26
List of Tables
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Renova Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Renova Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Renova Therapeutics Raises USD7.52 Million in Series C Financing 10
Renova Therapeutics Enters into Agreement with Janssen Pharma 11
Renova Therapeutics Enters into Licensing Agreement with Research Development Foundation 12
Renova Therapeutics Enters into Licensing Agreement with Stanford University 13
Renova Therapeutics Enters into Licensing Agreement with Research Development Foundation 14
Renova Therapeutics Inc, Key Competitors 15
Renova Therapeutics Inc, Key Employees 16
List of Figures
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Renova Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8